We joined Petros Grivas (University of Washington School of Medicine) at ESMO 2019 to discuss immune checkpoint inhibitors and novel agents in the treatment of metastatic urothelial cancer.
1. How have immune checkpoint inhibitors changed the treatment landscape for metastatic urothelial cancer? (0:04)
2. What progress has been made in identifying biomarkers of response to immune checkpoint inhibitors in urothelial cancer? (1:35)
3. What is the potential for combined treatment approaches using programmed cell death 1 (PD-1) and CTLA-4 inhibitors in urothelial cancer? (2:48)
4. How can we best manage toxicity from immune checkpoint inhibitors? (4:32)
5. Which novel agents are in clinical development for metastatic urothelial cancer? (6:37)
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
Speaker disclosure: Petros Grivas has acted as a consultant for AstraZeneca, Bayer, Biocept, Bristol-Myers Squibb, Clovis Oncology, Dendreon, Driver, EMD Serono, Exelixis, Foundation Medicine, Genentech, Genzyme, Heron Therapeutics, Janssen, Merck & Co., Mirati Therapeutics, Pfizer, Seattle Genetics and QED Therapeutics. He has been involved in educational programs with Bristol-Myers Squibb, Genentech Research Funding to Institution, AstraZeneca, Bayer, Genentech/Roche, Merck & Co., Mirati Therapeutics, Oncogenex, Pfizer, Clovis Oncology, Bavarian Nordic, Immunomedics, Debiopharm and Bristol-Myers Squibb.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Bladder Cancer
Stephen B Williams, ASCO 2021: TAR-200 in Combination with Cetrelimab in Muscle-invasive Urothelial Carcinoma of the Bladder
touchONCOLOGY joins Professor Stephen B Williams (Chief, Division of Urology, Professor of Urology and Radiology, Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA) at ASCO 2021 to discuss the efficacy of TAR-200 in combination with cetrelimab in participants with muscle-invasive urothelial carcinoma of the bladder. The abstract ‘A phase 3, multicenter, […]
Joaquim Bellmunt, ASCO 2021: 5-year Follow-up from the Phase 3 KEYNOTE-045 Trial
touchONCOLOGY joins Dr Joaquim Bellmunt (Director, Bladder Cancer Program, Beth Israel Deaconess Medical Center; Associate Professor of Medicine, Harvard Medical School, Boston, MA, USA) at ASCO 2021 to discuss the 5-year follow-up from the phase 3 KEYNOTE-045 trial. The abstract ‘A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial […]
Alison Birtle, ASCO GU 2021: Peri-operative Chemotherapy versus Surveillance in Upper Tract Urothelial Cancer
touchONCOLOGY joins Dr Alison Birtle (Consultant Oncologist and Honorary Senior Lecturer, Rosemere Cancer Centre, Lancashire Teaching Hospitals, Preston, UK) to discuss the updated primary and secondary analysis of the POUT trial in upper tract urothelial cancer (ClinicalTrials.gov Identifier: NCT01993979). The abstract “Updated outcomes of POUT: A phase III randomized trial of peri-operative chemotherapy versus surveillance […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!